Home - Products - Others - Other Targets - Fortunellin-6-beta-D-glucopyranoside (Acacetin-7-O-[2-O-rhamnosyl-6-O-glucosyl]-glucoside)

Fortunellin-6-beta-D-glucopyranoside (Acacetin-7-O-[2-O-rhamnosyl-6-O-glucosyl]-glucoside)

CAS No. 1218774-64-1

Fortunellin-6-beta-D-glucopyranoside (Acacetin-7-O-[2-O-rhamnosyl-6-O-glucosyl]-glucoside)( —— )

Catalog No. M32223 CAS No. 1218774-64-1

Reference standards.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 538 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fortunellin-6-beta-D-glucopyranoside (Acacetin-7-O-[2-O-rhamnosyl-6-O-glucosyl]-glucoside)
  • Note
    Research use only, not for human use.
  • Brief Description
    Reference standards.
  • Description
    Reference standards.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1218774-64-1
  • Formula Weight
    754.7
  • Molecular Formula
    C34H42O19
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO, Pyridine, Methanol, Ethanol, etc.
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • SP1

    SP1

  • 2-BFI hydrochloride

    2-BFI hydrochloride is a high-affinity agonist of I2-imidazoline receptor. 2-BFI hydrochloride can be used in studies about protection against stroke and acute inflammatory immune disease.

  • Adrenocorticotropic ...

    Adrenocorticotropic Hormone (ACTH) (4-10) is an agonist of potent melanocortin(MC4R) receptor.In humans, Adrenocorticotropic Hormone (ACTH) (4-10)?enters the cerebral fluid compartment after intranasal application and leads to a?decrease in total body fat after 6 weeks of continuous treatment.